To the Editor The Invited Commentary in a recent issue of JAMA Internal Medicine by Green and Gilbert1 is interesting and informative. Green and Gilbert commended the Research Letter by Arens and colleagues2 that reported a case series of counterfeit alprazolam (Xanax; Pfizer) tablets containing fentanyl and etizolam. Green and Gilbert emphasize that the current outbreak of illicitly synthesized fentanyl is remarkable for its wider geographic reach, more diverse groups of users, and a variety of fentanyl analogues being synthesized illicitly in clandestine laboratories.1
Ruan X, Wu H, Sehgal N. Intravenous Fentanyl and Potential Mortality. JAMA Intern Med. 2017;177(2):290–291. doi:10.1001/jamainternmed.2016.8753
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: